SCHEMBL19934828

SCHEMBL19934828

CC(C)(C)OC(=O)N1CCCC(CN/C=C(\N)Cl)C1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ACKR3 P25106 1/20 0.47
KDM1A O60341 1/20 0.45
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 1/20 0.45
MAPT P10636 1/20 0.45
KMT2A Q03164 1/20 0.45
GLS O94925 2/20 0.44
HTR6 P50406 6/20 0.43
BCHE P06276 4/20 0.43
BACE1 P56817 2/20 0.43
CTSD P07339 1/20 0.43
SCN9A Q15858 1/20 0.41
NR1H2 P55055 1/20 0.40
HPGD P15428 1/20 0.40
IRAK1 P51617 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12065342 0.84 ACKR3 (0.51) ACKR3KDM1AMEN1ALDH1A1MAPT
SCHEMBL24862784 0.83 ACKR3 (0.48) ACKR3KDM1AMEN1ALDH1A1MAPT
SCHEMBL13181804 0.81 ACKR3 (0.53) ACKR3KDM1AMEN1ALDH1A1MAPT
SCHEMBL2025339 0.80 ACKR3 (0.53) ACKR3KDM1AMEN1ALDH1A1MAPT
SCHEMBL2025336 0.80 ACKR3 (0.53) ACKR3KDM1AMEN1ALDH1A1MAPT
SCHEMBL23747111 0.80 ACKR3 (0.57) ACKR3KDM1AMEN1ALDH1A1MAPT
SCHEMBL18768306 0.79 ACKR3 (0.53) ACKR3KDM1AMEN1ALDH1A1MAPT
SCHEMBL4013908 0.78 ACKR3 (0.60) ACKR3KDM1AMEN1ALDH1A1MAPT
SCHEMBL4014855 0.78 ACKR3 (0.60) ACKR3KDM1AMEN1ALDH1A1MAPT
SCHEMBL17207589 0.78 ACKR3 (0.57) ACKR3KDM1AMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018041947-A1 IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASES OR CANCERS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2018-03-08 WO disclosed